Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

By Deena Beasley (Reuters) -People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

The first trial of a new monthly weight loss jab has shown jaw-dropping results compared to Wegovy and Mounjaro.

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

A new trial has found that a weight loss drug taken monthly helps people to lose 20 percent of their body weight. Other weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular ...

Amgen's experimental obesity drug MariTide showed promising weight loss results with fewer side effects, according to a ...